Mutations in different regions of the genome of hepatitis C virus genotype 1b and association with response to interferon therapy

Zhang,Lin; Han,Feng; Zhang,Dan; Dou,Xiao-Guang

doi:10.3892/ijmm.2012.1155

December 2012 Volume 30 Issue 6

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

December 2012 Volume 30 Issue 6

Full Size Image

Article

Mutations in different regions of the genome of hepatitis C virus genotype 1b and association with response to interferon therapy

Authors:
- Lin Zhang
- Feng Han
- Dan Zhang
- Xiao-Guang Dou
View Affiliations / Copyright

Affiliations: Department of Infectious Disease, Sheng Jing Hospital of China Medical University, Shenyang 110004, P.R. China
Pages: 1438-1442
|
Published online on: October 15, 2012

https://doi.org/10.3892/ijmm.2012.1155
Expand metrics +

Abstract

The aim of this study was to investigate the association of mutations in the E2/NS1 [hypervariable regions 1 and 2 (HVR1 and HVR2)] and NS5A regions of the hepatitis C virus (HCV) genome and the effectiveness of interferon (IFN) therapy, and assess whether the degree of heterogeneity of HCV quasispecies predicts response to IFN treatment. Fourteen patients infected with HCV genotype 1b (HCV-1b) who were treated with pegylated IFN-α-2a and ribavirin for 24 weeks, were studied. E2/NS1 and NS5A gene segments were amplified by reverse-transcription polymerase chain reaction. HCV quasispecies heterogeneity in the E2/NS1 region was determined by cloning and sequencing. Mutations in the NS5A region were detected by direct sequencing. The heterogeneity of HCV quasispecies in the HVR1 was significantly greater in the non-responder group than in the responder group, but was not significant for HVR2 or NS5A. The correlation between mutations in IFN sensitivity-determining region (ISDR, NS5A2209-2248) and IFN sensitivity could not be supported. The degree of quasispecies heterogeneity in HVR1, but not in HVR2 and NS5A, may be predictive of response to IFN therapy. An ISDR may not apply to patients infected with HCV-1b.

View Figures

View References

1.	M MasaroneM PersicoAntiviral therapy: why does it fail in HCV-related chronic hepatitis?Expert Rev Anti Infect Ther9535543201110.1586/eri.11.1021609265
2.	M RipoliV PazienzaImpact of HCV genetic differences on pathobiology of diseaseExpert Rev Anti Infect Ther9747759201110.1586/eri.11.9421905784
3.	GG XuSM WuXQ ZhouClinical characteristics of 638 patients infected with hepatitis C virus by post blood transfusion, in ShanghaiZhonghua Liu Xing Bing Xue Za Zhi323883912011(In Chinese)
4.	DA SteinhauerE DomingoJJ HollandLack of evidence for proofreading mechanisms associated with an RNA virus polymeraseGene122281288199210.1016/0378-1119(92)90216-C1336756
5.	A NeumannN LamH DahariHepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapyScience282103107199810.1126/science.282.5386.103
6.	M MartellJI EstebanJ QuerHepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distributionJ Virol663225322919921313927
7.	JM PawlotskyHepatitis C virus population dynamics during infectionCurr Top Microbiol Immunol299261284200616568902
8.	C ArgentiniD GenoveseS DettoriM RapicettaHCV genetic variability: from quasispecies evolution to genotype classificationFuture Microbiol4359373200910.2217/fmb.09.819327119
9.	MM ElHefnawiS ZadaIA El-AzabPrediction of prognostic biomarkers for interferon-based therapy to hepatitis C virus patients: a meta-analysis of the NS5A protein in subtypes 1a, 1b, and 3aVirol J15130201010.1186/1743-422X-7-13020550652
10.	BI YehKH HanHW LeeFactors predictive of response to interferon-alpha therapy in hepatitis C virus type 1b infectionJ Med Virol66481487200210.1002/jmv.216911857525
11.	I AbbateO Lo IaconoR Di StefanoHVR-1 quasispecies modifications occur early and are correlated to initial but not sustained response in HCV-infected patients treated with pegylated-or standard-interferon and ribavirinJ Hepatol40831836200410.1016/j.jhep.2004.01.019
12.	G SquadritoG RaffaT RestucciaIs investigation of hepatitis C virus NS5A gene heterogeneity a tool for predicting long-lasting response to interferon therapy in patients with HCV-1b chronic hepatitis?J Viral Hepat9360369200210.1046/j.1365-2893.2002.00379.x12225331
13.	L ZhangGZ ZhaoY LiDynamic changes of HVR1 quasispecies in chronic hepatitis C after IFN therapyWorld Chin J Digestol111821842003(In Chinese)
14.	P FaciA ShimodaD WongPrevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 proteinProc Natl Acad Sci USA931539415399199610.1073/pnas.93.26.153948986822
15.	YK ShimizuH IgarashiT KiyoharaA hyperimmune serum against a synthetic peptide corresponding to the hyper-variable region 1 of hepatitis C virus can prevent viral infection in cell culturesVirology223409412199610.1006/viro.1996.0497
16.	N EnomotoI SakumaY AsahinaMutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C 1b infectionN Engl J Med3347781199610.1056/NEJM1996011133402038531962
17.	M GerottoF Dal PeroP PontissoTwo PKR inhibitor HCV proteins correlate with early but not sustained response to interferonGastroenterology11916491655200010.1053/gast.2000.2023011113086
18.	H KhorsiS CsatelainA WyseurMutations of hepatitis C virus 1b NS5A _2209–2248 amino acid sequence do not predict the response to recombinant interferon-alfa therapy in French patientsJ Hepatol27727719979252076
19.	S ZeuzemJH LeeWK RothMutations in the nonstructural protein 5A gene of European hepatitis C virus isolates and response to interferon alphaHepatology25740744199710.1002/hep.5102503419049228
20.	K ChayamaF SuzukiA TsubotaAssociation of amino acid sequence in the PKR-eIF2 phosphorylation homology domain and response to interferon therapyHepatology3211381144200010.1053/jhep.2000.1936411050067